Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease

Boi, Laura

First

Methodology

;Pisanu, Augusta

Methodology

;Greig, Nigel

Conceptualization

;Scerba, Michael T

Methodology

;Tweedie, David

Investigation

;Mulas, Giovanna

Methodology

;Fenu, Sandro

Conceptualization

;Carboni, Ezio

Conceptualization

;Spiga, Saturnino

Conceptualization

;Carta, Anna R

Last

Project Administration

2019-01-01

---

Abstract

Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l-dopa-induced dyskinesia, a motor complication associated with l-dopa therapy in Parkinson's disease. The efficacy of thalidomide and the more potent derivative 3,6'-dithiothalidomide on dyskinesia was tested in the 6-hydroxydopamine Parkinson's disease model.